Purpose Earlier studies have shown that home care during the neutropenic phase after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is medically safe, with positive outcomes. However, there have been few results on long-term outcomes after home care. The aims of this study were to compare general health, symptom occurrence, and selfefficacy in adult survivors who received either home care or hospital care during the early neutropenic phase after allo-HSCT and to investigate whether demographic or medical variables were associated with general health or symptom occurrence in this patient population.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-established treatment option for hematological diseases and inborn errors of metabolism. The transplantation can offer an opportunity for long-term disease control and potential cure [1] . In the past decade, the high toxicity and mortality associated with allo-HSCT have been reduced due to several improvements such as individualized pretreatment, better genomic tissue typing, and improved supportive care [2] . The number of patients eligible for allo-HSCT has increased as a result of these improvements, and the introduction of less toxic reduced-intensity conditioning (RIC) has made it possible to admit elderly patients, i.e., those over 65 years, and those with comorbidities, e.g., heart/kidney disorders, pretransplant infections, or diabetes [2] .
During the early neutropenic phase after allo-HSCT, patients are usually treated in isolation at the hospital. Russell and colleagues [3] described successful treatment of patients in an outpatient setting in 1992, encouraging us to implement home care for patients treated at the Center for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital, Huddinge, Sweden. Since 1998, patients admitted to CAST have been offered the choice of hospital or home care during their first weeks in the early neutropenic phase. In 2000, Svahn et al. [4] showed that home care was a medically safe alternative for these patients and this has been confirmed in other outpatient care settings [5, 6] . Several medical advantages related to home care have been described, such as fewer days with fever and total parenteral nutrition. Moreover, in a study with matched patients, there was a lower rate of transplant-related mortality (TRM) and improved survival with home care compared to hospital care [7] . There was also a lower incidence of acute graft-versus-host disease (GVHD) grades II-IV in the home care group compared to the controls. Also, home care and the number of days at home have been shown to be correlated with a lower risk of acute GVHD [8] . After allo-HSCT, the incidence of acute GVHD ranges from 10 to 80 % and that for chronic GVHD 30 to 70 % [9] . Both acute and chronic GVHD are significant threats to quality of life and mortality [10] [11] [12] . Acute GVHD, especially grades III-IV, is a major cause of morbidity and mortality in the early phase after allo-HSCT [13] . Chronic GVHD occurs in a later phase after allo-HSCT. A number of long-term survivors of allo-HSCT have reported disease-and treatment-related problems that may last for a considerable time, with possible negative effects on well-being and quality of life [14] [15] [16] [17] [18] [19] . Quality of life has been related to different concepts, and one of them is self-efficacy. According to Bandura [20, 21] , self-efficacy consists of beliefs and/or perceptions that form the basis of motivation, well-being, and self-fulfillment [20] . Low self-efficacy has been associated with psychological distress and poorer quality of life in cancer patients [22, 23] . We recently showed that regardless of the care setting, patients reported high satisfaction with the care and support given by the staff during the acute post-transplantation phase [24] , suggesting that home care is at least as satisfying as hospital care.
Although studies have indicated that home care during the neutropenic phase is medically safe, with better survival, less GVHD, better nutritional status, and is psychosocially wellaccepted by patients in the short term, there is limited knowledge regarding the long-term effects and outcomes of these patients' life situation. The number of patients with home care after allo-HSCT is increasing at our center, so there is a need to evaluate several aspects of this treatment option. We therefore wanted to investigate whether patients with home care also had better general health, less symptom burden, and better self-efficacy in the long run than patients treated in hospital. Thus, the primary aim was to compare general health, symptom occurrence, and self-efficacy in longterm adult survivors who had received either home care or hospital care during the early neutropenic phase after allo-HSCT. The secondary aim was to investigate whether demographic or medical variables were associated with general health or symptom occurrence in this patient population.
Methods and patients

Sample
This cross-sectional survey is part of a larger study on the life situation of HSCT in survivors of working age, i.e., 18-65 years old [25] . Participants were identified from the European Blood and Marrow Transplantation Registry at the transplantation center, Karolinska University Hospital, Huddinge, Sweden. Eligible for participation were 171 survivors who underwent an HSCT due to a hematological disease, were cared for in hospital or at home during the neutropenic phase between January 1998 and June 2008, and were ≥18 years at allo-HSCT, in addition, lived in Sweden and aged between 19 and 65 years at data collection in May 2009. Patients without a Swedish personal identification number and those between <18 and >65 years at the time of data collection were excluded. Three percent of the eligible patients did not receive the request, due to administrative failures. Study information and a questionnaire were sent out by post (n=166) with a response rate of 70 % after one reminder (Fig. 1 ). The response rates were 66 % in the hospital and 83 % in the home care group. Patients agreed to participate by signing an informed consent document, and the study was approved by the Regional Ethical Review Board (Dnr 2009/540-32).
Clinical setting
Before allo-HSCT, patients who fulfilled the criteria for home care [26] had the opportunity to choose between hospital care and home care during the neutropenic phase. The conditioning and stem cell infusion were administered in hospital, and all patients received conventional prophylaxis against GVHD [27] , bacterial, and fungal infections [28] . Patients with home care went home median day 1 after HSCT (range 0-8) and stayed at home for median 17 day (range . During the neutropenic phase, patients in home care were visited and cared for on a daily basis by experienced nurses from the transplantation center, and each afternoon, a physician called the patient to check on the patient's well-being and to make appropriate modifications regarding treatment and medication. If there was any sign of unstable vital parameters or acute GVHD that could not be taken care of at home, patients were re-admitted to the transplant unit.
Data collection
Data were collected using a Swedish comprehensive questionnaire, previously used for women with breast cancer [29] , adapted to fit our patient group [25] . The questionnaire consists of a range of different validity-and reliabilitytested scales or parts of scales. The questionnaire took approximately 20 min to complete. In the present study, we report data from the questionnaire regarding demographic characteristics, general health, symptom occurrence, and self-efficacy.
Demographic characteristics Demographic characteristics included gender, age, marital status, living situation, and occupational status.
General health General health was assessed using one item from the Short Form 36 (SF-36) [30] : "How would you rate your overall health?" The single item has five response alternatives: "excellent" (100 points), "very good" (75 points), "good" (50 points), "fair" (25 points), and "poor" (0 points). The responses were also divided into "good health" (>50 points) and "poor health" (<50 points).
Symptom occurrence Symptom occurrence was assessed with part of the Symptom Frequency, Intensity, and Distress Questionnaire for Stem Cell Transplantation (SFID-SCT), developed by Larsen et al. [31] . It consists of 46 items on symptoms and asks for the occurrence, i.e., whether or not the symptom has been present during the previous week. The 15 most frequent symptoms were ranked, and numbers of symptoms per patient were summed. Symptoms of anxiety and depression were assessed using the 14-item Hospital Anxiety and Depression Scale (HADS) [32] . It consists of two subscales, one for depression (seven items) and one for anxiety (seven items). The items are graded on a four-point Likert scale. Subscale scores range from 0 (no distress) to 21 (maximum distress). The responses were divided into none (0-8) or case (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) [32, 33] . Cases are considered clinically significant. In this study, the Cronbach's alpha for anxiety was 0.87 and for depression was 0.85. Alpha values were higher than 0.70 and were therefore considered as acceptable [34] .
Self-Efficacy Self-Efficacy was measured with three items derived from the General Self-Efficacy Scale (GSE). The GSE was created to predict coping with daily difficulties as well as adaptation after experiencing various kinds of stressful life events [35] . Each item refers to a successful coping and implies an internal-stable attribution of success. Based on psychometrical analysis of item's function [36] , these three items from the scale were chosen for inclusion: (1) "I'm good at handling unexpected situations," (2) "I can solve most problems if I really want to," and (3) "No matter what happens in my life, I feel confident I can handle it." Each item has a five-point Likert scale. The alternative response options were "always" (100 points), "often" (75 points), "sometimes" (50 points), "seldom" (25 points), and "never/hardly ever" (0 points). The means for the three items were summed and divided by the total number of items. The higher the score, the better self-rated self-efficacy. Cronbach's alpha was 0.84.
Clinical characteristics Clinical characteristics were gathered from the patients' medical records including diagnosis, conditioning, stem cell source, donor type, acute GVHD, chronic GVHD, and clinical status at HSCT and at data collection.
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and Statistica version 10.0 (Statsoft Inc., Tulsa, OK, USA). A statistical significance level of P <0.05 was chosen. Descriptive statistics were used to summarize the demographic and clinical characteristics of the study sample. The Mann-Whitney U test was used to test differences between two independent groups (e.g., home and hospital) in variables at an ordinal, interval, or ratio level. Differences between the groups in variables at a nominal level were tested using the chi-square test or Fisher's exact test if appropriate. Logistic regression analysis was used to analyze the dependent variables, "general health" (good vs. poor) and "symptom occurrence" (<15 symptoms vs. ≥15 symptoms) for association with the following independent variables: caring context (home /hospital), gender (male/female), diagnosis, donor (HLA-identical sibling/unrelated), clinical status (high/low), age (<49/≥49 years), conditioning (MAC/ RIC),TBI (yes/no), aGVHD (yes/no), cGVHD (yes/no), stem cell source (BM, PBSC/cord blood), time since HSCT (<5/ ≥5 years), and self-efficacy [0 points (never/hardly ever)-100 points ("always")]. The 95 % confidence interval (CI) and estimates of the odds ratio (OR) are presented. In the univariate analysis, the independent variables with a p value of <0.2 were introduced into the multivariate backwards stepwise analysis [37] .
Results
Patient characteristics
Altogether, 117 patients participated (n=51 female, n=66 male) with a median age of 49 (21-65) years and median time of 5 (1-11) years since HSCT. Fifty percent had a college degree, and 60 % were working at the time of data collection. The majority of patients (n=78) were cared for in hospital and the remaining (n=39) at home. There were no statistically significant differences in demographic or clinical characteristics between hospital and home (Tables 1 and 2 ). Forty-three percent of patients had acute leukemia, 59 % received myeloablative conditioning (MAC), and 41 % received reduced intensive conditioning (RIC). As part of the conditioning, 42 % received total body irradiation (TBI). The majority (78 %) received peripheral blood stem cells (PBSC). In this study, 70 % of patients were assessed as "low risk", i.e., first complete remission or first chronic phase at data collection. At some time, 63 % of the patients had developed acute GVHD and 45 % chronic GVHD. Twenty-seven patients developed acute GVHD grade II-III (29 % hospital care and 13 % home care). One patient in the home care group developed severe chronic GVHD.
Comparing the non-responders (n=49) with the responders (n=117) (Fig. 1) , we found that fewer the non-responders received home care (16 %, p=0.02), had more sibling donors (55 %, p=0.042), and had a lower incidence of chronic GVHD (25 %, p=0.03). No other statistically significant differences were found.
Comparisons of general health, symptom occurrence, and self-efficacy Overall, there were no significant differences regarding general health, symptom occurrence, or self-efficacy between patients in hospital and those in home care ( Table 3) . The majority of patients in both hospital care (77 %) and home care (78 %) rated their general health as good (Table 3) . Median 14 symptoms were reported by patients in both hospital (0-36) and home care (1-29) .
The five symptoms reported most frequently by patients in hospital care were tiredness (82 %), impaired fitness (68 %), loss of energy (67 %), lack of sexual interest (59 %), and difficulty in remembering (57 %). The most frequently reported symptoms for patients in home care were tiredness (68 %), impaired fitness (58 %), lack of sexual interest (58 %), dissatisfied with body (57 %), and loss of energy (55 %) ( Table 4) . A total of 18 % patients in hospital care and 18 % in home care were classified as cases of anxiety, while 12 % of patients in hospital care and 18 % in home care were classified as cases of depression (Table 3) . Finally, patients in both groups reported a high degree of self-efficacy, with a median score of 75 out of 100 (Table 3) .
Factors associated with general health and symptom occurrence
Multivariate logistic regression analysis on the study population (n=117) showed that poor general health was associated with receiving a cord blood HSCT (OR 19.1, CI 1.42-258.0, p=0.025), acute GVHD (OR 4.55, CI 1.19-17.4, p=0.025), and a low self-efficacy at follow-up (OR 0.95, CI 0.92-0.98, p=0.002). A high symptom occurrence (>15 current symptoms) was associated with being female (OR 2.83, CI 1.17-6.87, p=0.02), acute GVHD, (OR 4.09, CI 1.51-11.0, p= 0.005), and a low self-efficacy at follow-up (OR 0.95, CI .0.92-0.98, p<0.001) ( Table 5 ).
Discussion
The overall goals of this study were to compare general health, symptom occurrence, and self-efficacy in adult long-term survivors who received home care or hospital care during the early neutropenic phase after allo-HSCT and to investigate whether demographic or medical variables were associated with general health or symptom occurrence in this patient population. Contrary to our expectations, no differences regarding general health, symptom occurrence, or self-efficacy were found between the groups. Factors not directly related to caring context were associated with a poorer general health, such as acute GVHD, a low self-efficacy, and stem cells from cord blood. In general, a high symptom occurrence was associated with acute GVHD, being female, and low self-efficacy.
Earlier reports suggest that home care during the early neutropenic phase is medically safe [7, 26] and psychosocially well-accepted by patients [24] . Patients with home care have been shown to have fewer days with fever and use of parenteral nutrition, less moderate-to-severe acute GVHD, a lower rate of transplant-related mortality, and improved survival compared to matched patients treated in hospital during the neutropenic phase after allo-HSCT [7, 38] . The higher incidence of acute GVHD in hospital has been related to environmental factors such as higher degree of exposure to various infectious agents that are known to trigger GVHD [39] and the hospital as an alien environment acting as a stress-related trigger of acute GVHD through various inflammatory cytokines [40] and activation of T cells [41] . Patients at home also have a better oral nutritional intake than patients in hospital [26] which has been shown to correlate with lower severity of acute GVHD [42] . To some extent and surprisingly, earlier reported short-term benefits of home care do not appear to persist in the long term, as no significant differences were found in the present study between patients receiving home or hospital care, regarding general health, symptom occurrence, or self-efficacy. We had assumed that a lower prevalence of acute GVHD particular in patients treated at home would be of benefit to general health and symptom occurrence in the long term. In line with this idea, the multivariate analysis including all patients revealed that acute GVHD was an independent risk factor for poor general health and high symptom occurrence at follow-up, but contrary to (3) 1 (3) a Included full-time work, part-time work up to 75 %, studies, parental leave previous studies from our center, only a trend of less severe acute GVHD (grades II-III) was observed in the home care group (hospital care 29 %, home care 13 % p=0.063). In previous studies, chronic GVHD has also been shown to predict patients' quality of life [10] , but as with acute GVHD in the present study, no differences were observed between the groups. Nor did we observe any association between chronic GVHD and general health in the regression analysis, which can presumably could be explained by the fact that very few patients developed severe chronic GVHD. BM bone marrow, GVHD graft-versus-host disease, high risk beyond first complete remission, low risk first complete remission or first chronic phase, MAC myeloablative conditioning, MDS myeloid dysplastic syndrome, MPS myeloproliferative syndrome, MUD matched unrelated donor, PBSCs peripheral blood stem cells, RIC reduced-intensity conditioning, SAA severe aplastic anemia, Sib HLA-identical sibling, TBI total body irradiation, *acute GVHD of grades 0-I vs. grades II-III In addition to acute GVHD, an association was identified between poor general health and the use of cord blood. However, the interpretation of this finding must be done with caution, since only four patients received cord blood. Still, we recently showed a reduced survival and high transplantrelated mortality in adult patients who received cord blood as stem cell source [43] . Gender was also identified to be predictor of poor general health, i.e., female patients had a significantly higher numbers of symptoms in accordance with previous report in the early phase post-HSCT [44] . Finally, high self-efficacy was associated with better general health and lower symptom occurrence. This is in line with other studies where self-efficacy has been reported to influence the quality of life of HSCT patients [45] and also of mixed groups of cancer patients [22, 23] . In theory, self-efficacy is not a static characteristic and can be altered by behavior, by internal personal factors in the form of cognitive, affective, and biological events, and by external environment [21] . To identify self-efficacy and introduce targeted preventive support in patients with a low degree of self-efficacy early in the course 9 (12) 7 (18) a Scores range from 0 to100, with higher scores representing higher level of health and self-efficacy of allo-HSCT may therefore be of importance in being able to better prevent long-term effects on health and symptom occurrence [46] . Patients should be encouraged to take an active role in treatment, by being well informed about essential issues in order to be able to care for themselves before and after allo-HSCT. Importantly, the majority of patients (hospital care 77 %, home care 78 %) reported having good general health, which is in line with longitudinal studies where more than 60 % of patients have reported good to excellent quality of life 1-4 years after HSCT [11, 47] , and some patients have even reported an improved health [48] . However, at the same time, both of our groups reported a median of 14 current symptoms that had an impact on general health at a median follow-up time of 5 years after HSCT. This finding is consistent with our previous work, where 80 % of patients having good health despite a high incidence of symptoms and impaired functional status 2-4 years after HSCT [49] . This discrepancy can be explained and been related to a response shift i.e., patients might have changed their view of life, accepting a lower level of functioning. This shift would be explained by a reappraisal of the patient's values due to personal growth, as has been seen after a cancer diagnosis and an intensive treatment [50, 51] .
In both groups, four symptoms were within the five frequently occurring symptoms, fatigue including tiredness, impaired fitness, loss of energy, and lack of sexual interest. This is important to note since numerous factors known to contribute to fatigue, impaired fitness, and loss of energy are treatable, such as pain, emotional distress, and anemia [52] . Importantly, sleep disturbance was reported among the ten most occurring symptom coherent with earlier presented symptom occurrence and symptom cluster in this patient group [52, 53] . Moreover, a lack of sexual interest was also reported among the top five symptoms in both groups. Although in most cases a spontaneous recovery of sexual activity occurs, but in some, survivors experience sexual dysfunction been reported 5-10 years post-HSCT [54] . Even though the HSCT survivors struggle with fears and uncertainty about relapse and their long-term health, only a minority of the patients in the present study were classified as cases of depression (hospital care 18 %, home care 18 %) or anxiety (hospital care 12 %, home care 18 %). Depression has earlier been reported in 9 to 20 % of long-term survivors [55] [56] [57] and thus seems to occur only in a minority of the patients.
We acknowledge that this single-center study on survivors of HSCT, with its cross-sectional design and rather small sample size had methodological limitations. There were no significant differences in demographic or clinical characteristics between the participants in the two groups. The majority of non-responders had a sibling donor and a lower incidence of chronic GVHD, which may indicate that they had a better # General health score ≥50=good GH, <50=poor GH *Logistic regression analysis, multivariate, backwards stepwise analysis **Self-efficacy score 0 ("never/hardly ever")-100 ("always") points general health than the responders. However, we believe that the result of the current study will add new knowledge in the field, since this study cohort was unique; this is one of the first studies to focus on long-term effects of treatment at home after allo-HSCT. A prospective long-term study is already being carried at our center, with the overall aim of describing the life situation during the HSCT-tracetory and also to identify when the positive short-term outcomes of home care decline or shift. This is an information that could be important in order to predict the ability of the patient to adjust to the consequences of their disease and treatment.
In conclusion, the study results indicate that there are no long-term differences in terms of general health, symptom occurrence, and self-efficacy between patients who receive hospital care and those with home care. There was a high incidence of symptoms in both groups, which shows the substantial long-term effects of allo-HSCT. Poor general health was associated with acute GVHD, low self-efficacy, and cord blood stem cells, while a high degree of symptom occurrence was associated with acute GVHD, female gender, and low self-efficacy. Based on these findings, we can consider home care to be a valid caring option for HSCT patients who prefer to stay at home during the early neutropenic phase.
